These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35006045)

  • 1. "Damned If You Do, Doomed If You Don't": A Socio-Medical Commentary on "Of Athletes, Bodies and Rules: Making Sense of
    Holtzman B; Ackerman KE
    J Law Med Ethics; 2021; 49(4):661-665. PubMed ID: 35006045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Of Athletes, Bodies, and Rules: Making Sense of
    Winkler M; Gilleri G
    J Law Med Ethics; 2021; 49(4):644-660. PubMed ID: 35006046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caster Semenya, athlete classification, and fair equality of opportunity in sport.
    Loland S
    J Med Ethics; 2020 Sep; 46(9):584-590. PubMed ID: 32690761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outstanding performances during elite-standard short and middle-distance finals and the hyperandrogenism regulation-A detailed analysis of Caster Semenya's results.
    Ospina-Betancurt J; Zakynthinaki MS
    J Sports Sci; 2020 Mar; 38(6):703-709. PubMed ID: 32050847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policing the boundaries of sex: a critical examination of gender verification and the Caster Semenya controversy.
    Cooky C; Dworkin SL
    J Sex Res; 2013; 50(2):103-11. PubMed ID: 23320629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The End of Compulsory Gender Verification: Is It Progress for Inclusion of Women in Sports?
    Ospina-Betancurt J; Vilain E; Martinez-Patiño MJ
    Arch Sex Behav; 2021 Oct; 50(7):2799-2807. PubMed ID: 34494166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A local criterion of fairness in sport: Comparing the property advantages of Caster Semenya and Eero Mäntyranta with implications for the construction of categories in sport.
    Camporesi S; Hämäläinen M
    Bioethics; 2021 Mar; 35(3):262-269. PubMed ID: 33184909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethics of Regulating Competition for Women with Hyperandrogenism.
    Camporesi S
    Clin Sports Med; 2016 Apr; 35(2):293-301. PubMed ID: 26832978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Would it be ethical or legal for doctors in South Africa to administer testosterone-reducing drugs to Caster Semenya?
    McQuoid-Mason DJ
    S Afr Med J; 2019 Jul; 109(8):552-554. PubMed ID: 31456546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperandrogenic athletes: performance differences in elite-standard 200m and 800m finals.
    Ospina Betancurt J; Zakynthinaki MS; Martinez-Patiño MJ; Cordente Martinez C
    J Sports Sci; 2018 Nov; 36(21):2464-2471. PubMed ID: 29659337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administering drugs to an individual in a non-pathological situation: The Caster Semenya case.
    Jagadeesh N
    Indian J Med Ethics; 2020; V(2):139-143. PubMed ID: 32393456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global injustice in sport: The Caster Semenya ordeal - prejudice, discrimination and racial bias.
    Mahomed S; Dhai A
    S Afr Med J; 2019 Jul; 109(8):548-551. PubMed ID: 31456545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the Caster Semenya controversy: the case of the use of genetics for gender testing in sport.
    Wonkam A; Fieggen K; Ramesar R
    J Genet Couns; 2010 Dec; 19(6):545-8. PubMed ID: 20824315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When does an advantage become unfair? Empirical and normative concerns in Semenya's case.
    Camporesi S
    J Med Ethics; 2019 Nov; 45(11):700-704. PubMed ID: 31527141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Out of bounds? A critique of the new policies on hyperandrogenism in elite female athletes.
    Karkazis K; Jordan-Young R; Davis G; Camporesi S
    Am J Bioeth; 2012; 12(7):3-16. PubMed ID: 22694023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular diagnosis of 5α-reductase deficiency in 4 elite young female athletes through hormonal screening for hyperandrogenism.
    Fénichel P; Paris F; Philibert P; Hiéronimus S; Gaspari L; Kurzenne JY; Chevallier P; Bermon S; Chevalier N; Sultan C
    J Clin Endocrinol Metab; 2013 Jun; 98(6):E1055-9. PubMed ID: 23633205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperandrogenism and intersex controversies in women's olympics.
    Xavier NA; McGill JB
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3902-7. PubMed ID: 22990091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why are there no platypuses at the Olympics?: A teleological case for athletes with disorders of sexual development to compete within their sex category.
    Gamble N; Pruski M
    S Afr J Sports Med; 2020; 32(1):v32i1a7918. PubMed ID: 36818986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Female Hyperandrogenism in Elite Sports and the Athletic Triad.
    Hirschberg AL
    Semin Reprod Med; 2022 Mar; 40(1-02):32-41. PubMed ID: 34634825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The new policy on hyperandrogenism in elite female athletes is not about "sex testing".
    Sánchez FJ; Martínez-Patiño MJ; Vilain E
    J Sex Res; 2013; 50(2):112-5. PubMed ID: 23320653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.